Search papers, labs, and topics across Lattice.
This study evaluates a multi-chain chain-of-thought (CoT) reporter based on the Mistral-7B model for brain tumor MRI reporting, revealing significant diagnostic shortcomings, particularly in identifying meningiomas and metastases. By applying a supervised linear probe to the model's frozen segmentation features, the authors recover a high macro-F$_1$ score of 0.82 for tumor classification, demonstrating the latent diagnostic potential within the model. They introduce NeuroFusion, an assistive reporter that effectively surfaces this latent signal, achieving improved diagnostic accuracy and significantly lower latency compared to traditional methods while maintaining high schema validity in generated reports.
A novel approach reveals that existing MRI report generators can be enhanced to accurately diagnose brain tumors by leveraging latent features, achieving up to 92% accuracy in identifying meningiomas.
A capable brain-MRI report generator can still be, in effect, diagnostically silent. When a multi-chain chain-of-thought (CoT) reporter built on a medical Mistral-7B backbone is evaluated on held-out cohorts, it names most meningiomas and almost all metastases "glioma" (diagnosis recall 0.44/0.07). Yet the answer is not absent from the model: a supervised linear probe applied to its frozen segmentation features recovers the three tumour cohorts at 0.82 macro-F$_1$ (5-fold cross-validation; chance $\approx$0.33). We introduce NeuroFusion, an assistive reporter that surfaces this latent signal rather than overriding it: discriminative field-classifier heads over per-lesion features condition a fast, single-pass draft-then-review decoder on their committed outputs. Built on the identical Mistral backbone, this restores the diagnosis (meningioma 0.92, metastasis 0.75) and wins 8 of 9 prose-content comparisons across three held-out cohorts (RaTEScore, RadGraph-F$_1$, GREEN; Holm-corrected paired BCa), with no significant loss on the ninth, at 5-6x lower latency ($\approx$80 vs. 457 s/case). A controlled negative result sharpens the mechanism: a learned diagnosis pin that overrides the decoder instead of merely informing it collapses out-of-distribution metastasis recall to 0.03. Grammar-constrained decoding keeps 92.3% of records schema-valid, making every sentence entailment-checkable (7.5% contradicted vs. 36.8% for the direct baseline). In a blinded nine-case pilot, two board-certified neurologists independently rated NeuroFusion highest in every tumour type, the only system with zero critical errors, and gave it the top-rated sign-off in eight of nine cases (six outright, two ties).
